Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Phase 1
Active, not recruiting
- Conditions
- IgA Nephropathy
- Interventions
- Drug: BION-1301 Single DoseDrug: Placebo Single DoseDrug: BION-1301 Multiple DosesDrug: Placebo Multiple Doses
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT03945318
- Locations
- πΊπΈ
Chris Sholer, P.C., Oklahoma City, Oklahoma, United States
πΊπΈAmicis Research Center, Northridge, California, United States
πΊπΈNew York Nephrology, Clifton Park, New York, United States
Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
Phase 2
Terminated
- Conditions
- Asthma
- Interventions
- Drug: LOU064 100 mgDrug: Placebo
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT03944707
- Locations
- π·πΊ
Novartis Investigative Site, Ulyanovsk, Russian Federation
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Phase 1
Active, not recruiting
- Conditions
- High-risk Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03940352
- Locations
- πͺπΈ
Novartis Investigative Site, Madrid, Spain
πΊπΈDuke University Medical Center ., Durham, North Carolina, United States
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT03938454
- Locations
- πΊπΈ
University Of Alabama, Birmingham, Alabama, United States
πΊπΈUniversity of Connecticut Health Center, Farmington, Connecticut, United States
πΊπΈChildrens National Hospital, Washington, District of Columbia, United States
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT03930641
- Locations
- πΊπΈ
Novartis Investigative Site, Richmond, Virginia, United States
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT03927690
- Locations
- πΉπ·
Novartis Investigative Site, Kocaeli, Turkey
This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
Phase 2
Completed
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: LOU064 Arm 1Drug: LOU064 Arm 2Drug: LOU064 Arm 5Drug: LOU064 Arm 4Drug: Placebo armDrug: LOU064 Arm 3Drug: LOU064 Arm 6
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 311
- Registration Number
- NCT03926611
- Locations
- π¬π§
Novartis Investigative Site, Plymouth, United Kingdom
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
Phase 1
Completed
- Conditions
- Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT03918980
- Locations
- π³π±
Novartis Investigative Site, Leiden, Netherlands
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 517
- Registration Number
- NCT03917472
- Locations
- πΈπ°
Novartis Investigative Site, Zvolen, Slovakia
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
Phase 3
Completed
- Conditions
- Heart FailureErectile DysfunctionHeart Failure, Systolic
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT03917459
- Locations
- π©πͺ
Novartis Investigative Site, Wermsdorf, Germany